JP2010535232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535232A5 JP2010535232A5 JP2010520118A JP2010520118A JP2010535232A5 JP 2010535232 A5 JP2010535232 A5 JP 2010535232A5 JP 2010520118 A JP2010520118 A JP 2010520118A JP 2010520118 A JP2010520118 A JP 2010520118A JP 2010535232 A5 JP2010535232 A5 JP 2010535232A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- weight
- microcrystalline cellulose
- lauryl sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 119
- 150000001875 compounds Chemical class 0.000 claims 93
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 32
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 22
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 22
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 22
- 239000008108 microcrystalline cellulose Substances 0.000 claims 22
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 20
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 20
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 16
- 238000010276 construction Methods 0.000 claims 16
- 229960001681 croscarmellose sodium Drugs 0.000 claims 16
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 16
- 235000019359 magnesium stearate Nutrition 0.000 claims 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 15
- 238000000034 method Methods 0.000 claims 13
- 239000003937 drug carrier Substances 0.000 claims 12
- 239000003981 vehicle Substances 0.000 claims 12
- 239000002775 capsule Substances 0.000 claims 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 10
- 239000003826 tablet Substances 0.000 claims 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- -1 iodophenylamino Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- 239000007963 capsule composition Substances 0.000 claims 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims 4
- 239000007916 tablet composition Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical group OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 claims 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000000378 calcium silicate Substances 0.000 claims 1
- 229910052918 calcium silicate Inorganic materials 0.000 claims 1
- 235000012241 calcium silicate Nutrition 0.000 claims 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000012156 elution solvent Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229960004275 glycolic acid Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- RDSACQWTXKSHJT-UHFFFAOYSA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide Chemical compound C1CC1(CC(O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 229950006451 sorbitan laurate Drugs 0.000 claims 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims 1
- 229950004959 sorbitan oleate Drugs 0.000 claims 1
- 229950011392 sorbitan stearate Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 0 Cc1cc(*)c(*[S+](C2(CC(CO)O)CC2)O)c(NC2C(F)=CC(I)=CC2)c1F Chemical compound Cc1cc(*)c(*[S+](C2(CC(CO)O)CC2)O)c(NC2C(F)=CC(I)=CC2)c1F 0.000 description 3
- MBXSALCZABGXSF-UHFFFAOYSA-O COC(C=C(C(C1NC(C(C2)F)=CC=C2I)F)F)=C1N[S+](C[OH2+])C1(CC(CO)O)CC1 Chemical compound COC(C=C(C(C1NC(C(C2)F)=CC=C2I)F)F)=C1N[S+](C[OH2+])C1(CC(CO)O)CC1 MBXSALCZABGXSF-UHFFFAOYSA-O 0.000 description 1
- LBYBVDXPMFHXGU-UHFFFAOYSA-O COc(cc(c(F)c1Nc(ccc(I)c2)c2F)F)c1NCS(C1(CCCO)CC1)[OH2+] Chemical compound COc(cc(c(F)c1Nc(ccc(I)c2)c2F)F)c1NCS(C1(CCCO)CC1)[OH2+] LBYBVDXPMFHXGU-UHFFFAOYSA-O 0.000 description 1
- SOSDXQOQEZQHLZ-UHFFFAOYSA-O N=C(c(c(O)cc(F)c1F)c1Nc(c(F)c1)ccc1I)S(C1(CCCO)CC1)(O)[OH2+] Chemical compound N=C(c(c(O)cc(F)c1F)c1Nc(c(F)c1)ccc1I)S(C1(CCCO)CC1)(O)[OH2+] SOSDXQOQEZQHLZ-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/830,733 US8101799B2 (en) | 2005-07-21 | 2007-07-30 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US3446408P | 2008-03-06 | 2008-03-06 | |
| US3446608P | 2008-03-06 | 2008-03-06 | |
| US4488608P | 2008-04-14 | 2008-04-14 | |
| PCT/US2008/071392 WO2009018233A1 (en) | 2007-07-30 | 2008-07-28 | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014231450A Division JP6309880B2 (ja) | 2007-07-30 | 2014-11-14 | Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010535232A JP2010535232A (ja) | 2010-11-18 |
| JP2010535232A5 true JP2010535232A5 (enExample) | 2011-09-15 |
Family
ID=40304796
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520118A Pending JP2010535232A (ja) | 2007-07-30 | 2008-07-28 | Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
| JP2014231450A Expired - Fee Related JP6309880B2 (ja) | 2007-07-30 | 2014-11-14 | Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
| JP2017018477A Pending JP2017125021A (ja) | 2007-07-30 | 2017-02-03 | Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014231450A Expired - Fee Related JP6309880B2 (ja) | 2007-07-30 | 2014-11-14 | Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
| JP2017018477A Pending JP2017125021A (ja) | 2007-07-30 | 2017-02-03 | Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2184984A4 (enExample) |
| JP (3) | JP2010535232A (enExample) |
| KR (3) | KR20140098185A (enExample) |
| CN (2) | CN103479604B (enExample) |
| AP (1) | AP2817A (enExample) |
| AU (2) | AU2008282338B2 (enExample) |
| BR (1) | BRPI0815659A2 (enExample) |
| CA (1) | CA2693390C (enExample) |
| CO (1) | CO6470808A2 (enExample) |
| CR (1) | CR11244A (enExample) |
| DO (1) | DOP2010000045A (enExample) |
| EA (2) | EA020624B1 (enExample) |
| EC (1) | ECSP109910A (enExample) |
| HN (1) | HN2010000203A (enExample) |
| IL (1) | IL203296A (enExample) |
| MA (1) | MA31881B1 (enExample) |
| MX (1) | MX2010001244A (enExample) |
| NZ (1) | NZ582929A (enExample) |
| PH (1) | PH12015501914A1 (enExample) |
| SV (1) | SV2010003469A (enExample) |
| TN (1) | TN2010000049A1 (enExample) |
| WO (1) | WO2009018233A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| US8808742B2 (en) * | 2008-04-14 | 2014-08-19 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
| KR101822319B1 (ko) * | 2008-09-09 | 2018-01-25 | 에프. 호프만-라 로슈 아게 | 아실 설폰아미드의 다형체 |
| TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| UY32486A (es) * | 2009-03-11 | 2010-10-29 | Ardea Biosciences Inc | Tratamiento del cáncer de páncreas |
| SG174272A1 (en) * | 2009-03-11 | 2011-10-28 | Ardea Biosciences Inc | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
| CN102666512B (zh) | 2009-10-13 | 2014-11-26 | 奥斯特姆医疗公司 | 对疾病治疗有用的mek抑制剂 |
| EP2491015A1 (en) * | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| CN102649773A (zh) * | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途 |
| BR112013027448A2 (pt) * | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | terapia de combinação com hsp90 |
| UA113850C2 (xx) * | 2011-05-27 | 2017-03-27 | Хіральний синтез n-{3,4-дифтор-2-$(2-фтор-4-йодфеніл)аміно]-6-метоксифеніл}-1-$2,3-дигідроксипропіл]циклопропансульфонамідів | |
| US20150132301A1 (en) * | 2011-12-09 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Combination Therapy for Treatment of Cancer |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| KR20150013332A (ko) * | 2012-05-31 | 2015-02-04 | 바이엘 파마 악티엔게젤샤프트 | 간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커 |
| WO2013184572A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| PL3702351T3 (pl) * | 2012-10-19 | 2024-04-02 | Array Biopharma, Inc. | Formulacja zawierająca inhibitor mek |
| EP2916859B1 (en) | 2012-11-02 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| EP2848246A1 (en) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| CN106535931A (zh) * | 2014-08-25 | 2017-03-22 | 艾慕恩治疗公司 | 卵蛋白制剂及其制备方法 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| AU2018283289B2 (en) | 2017-06-16 | 2021-03-25 | Beta Pharma, Inc. | Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021067772A1 (en) * | 2019-10-04 | 2021-04-08 | Sumitomo Dainippon Pharma Oncology, Inc. | Axl inhibitor formulations |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| CN118834328B (zh) * | 2024-07-02 | 2025-09-16 | 江苏海洋大学 | 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| JP2575590B2 (ja) * | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 |
| JP3657002B2 (ja) * | 1992-08-25 | 2005-06-08 | ジー．ディー．サール アンド カンパニー | レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド |
| US7115632B1 (en) * | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| GEP20032999B (en) * | 1999-01-13 | 2003-06-25 | Warner Lambert Co | 1-Heterocycle Substituted Diarylamines |
| GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| CA2461227C (en) * | 2001-09-24 | 2012-05-15 | Jessie L.-S Au | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
| US20060089410A1 (en) * | 2002-07-17 | 2006-04-27 | Titan Pharmaceuticals, Inc. | Combination of chemotherapeutic drugs for increasing antitumor activity |
| JP2005535688A (ja) * | 2002-07-30 | 2005-11-24 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用 |
| BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
| CA2605381A1 (en) * | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | Crystal polymorphism of 4'-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3',5'-dimethylbiphenylcarboxylic acid hydrochloride |
| WO2007014011A2 (en) * | 2005-07-21 | 2007-02-01 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| JP2007099763A (ja) * | 2005-09-08 | 2007-04-19 | Toyama Chem Co Ltd | ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法 |
| TW200800150A (en) * | 2005-12-21 | 2008-01-01 | Organon Nv | Compounds with medicinal effects due to interaction with the glucocorticoid receptor |
-
2008
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/ko not_active Ceased
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/ja active Pending
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/ko not_active Ceased
- 2008-07-28 EA EA201000268A patent/EA020624B1/ru not_active IP Right Cessation
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/zh not_active Expired - Fee Related
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/es active IP Right Grant
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/en not_active Ceased
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 CA CA2693390A patent/CA2693390C/en not_active Expired - Fee Related
- 2008-07-28 EA EA201400552A patent/EA032294B1/ru not_active IP Right Cessation
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/pt not_active Application Discontinuation
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/ko not_active Ceased
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/en not_active Ceased
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 AP AP2010005134A patent/AP2817A/xx active
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/zh not_active Expired - Fee Related
-
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/es unknown
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/es unknown
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/fr unknown
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/es unknown
- 2010-01-29 CO CO10009526A patent/CO6470808A2/es not_active Application Discontinuation
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/es unknown
- 2010-01-29 CR CR11244A patent/CR11244A/es not_active Application Discontinuation
- 2010-02-19 MA MA32636A patent/MA31881B1/fr unknown
-
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
-
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004275469B2 (en) | HRT formulations | |
| GB2053681A (en) | Sustained release pharmaceutical composition | |
| JP2016513683A (ja) | 複素環化合物およびその使用 | |
| US20250120919A1 (en) | Compositions of midodrine and methods of using the same | |
| WO2003082805A1 (en) | Low water-soluble venlafaxine salts | |
| US7772273B2 (en) | Stabilized atorvastatin | |
| US20030147957A1 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core | |
| EP3456729B1 (en) | CRYSTALLINE POLYMORPH OF 15ß-HYDROXY-OSATERONE ACETATE | |
| KR101923403B1 (ko) | 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물 | |
| WO2015015254A1 (en) | Pharmaceutical compositions of fingolimod | |
| WO2003082804A1 (en) | Venlafaxine besylate | |
| CN114867469A (zh) | 包含氨基甲酸酯化合物的口服药物组合物及其制备方法 | |
| CA2722802C (en) | Granulate comprising escitalopram oxalate | |
| US20110196032A1 (en) | Pharmaceutical Dosage Form of an Antidepressant | |
| KR20140045925A (ko) | 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물 | |
| WO2007075009A1 (en) | Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof | |
| CN119074728A (zh) | 用于高血压治疗的多重释放组合物 | |
| WO2020003196A1 (en) | Pharmaceutical composition of axitinib | |
| EP4593807A1 (en) | Palatable orodispersible formulation of vortioxetine | |
| JP7692889B2 (ja) | ＨＭＧ－ＣｏＡレダクターゼ阻害剤及びフェノフィブラートを含む医薬組成物 | |
| US9687475B1 (en) | Extended release pharmaceutical formulations with controlled impurity levels | |
| RU2850454C9 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОРЫ HMG-CoA РЕДУКТАЗЫ И ФЕНОФИБРАТ | |
| US20110263701A1 (en) | Gabapentin enacarbil compositions | |
| WO2022079591A1 (en) | Pharmaceutical composition of lasmiditan and process of preparation thereof | |
| HK40072206A (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |